Document 1233
 DOCN  M9591233
 TI    Therapy of pediatric AIDS.
 DT    9509
 AU    Wu LR; Capparelli EV; Connor JD; University of California at San Diego,
       USA.
 SO    Curr Opin Pediatr. 1995 Apr;7(2):214-9. Unique Identifier : AIDSLINE
       MED/95307661
 AB    Therapy of pediatric AIDS utilizes antiretroviral compounds; antibiotic,
       antifungal, and antiparasitic agents; and both active and passive
       immunization in a multifactorial approach. Currently, newly diagnosed
       pediatric AIDS cases are acquired predominantly through vertical
       transmission from HIV-infected mothers. Pediatric AIDS research is
       focused on strategies to prevent vertical transmission of HIV infection
       as well as therapy against opportunistic and progressive HIV disease.
       Zidovudine remains first-choice therapy for HIV infection and can reduce
       the rate of vertical transmission of HIV. Didanosine is also approved to
       treat HIV infection in pediatric AIDS. Other reverse transcriptase
       inhibitors are under investigation as alternative or combination
       therapies because of HIV resistance to zidovudine and didanosine.
       Alternative therapies for opportunistic infections are being
       investigated. Passive immunity with intravenous immunoglobulin is being
       reevaluated to determine efficacy in combination with other therapies.
       Finally, vaccination against usual childhood diseases with standard
       immunization schedules produces limited immunity, and alternative
       vaccination protocols warrant further investigation.
 DE    Acquired Immunodeficiency Syndrome/CONGENITAL/*THERAPY/  TRANSMISSION
       AIDS-Related Opportunistic Infections/THERAPY  Child
       Didanosine/THERAPEUTIC USE  Disease Transmission, Vertical  Human
       Immunization, Passive  Support, Non-U.S. Gov't  Support, U.S. Gov't,
       P.H.S.  Vaccination  Zidovudine/THERAPEUTIC USE  JOURNAL ARTICLE  REVIEW
       REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).